Molecular insight into pemetrexed as a partial agonist of PPAR <sub>γ</sub> through molecular dynamics simulations
Pemetrexed (PMX), a first-line chemotherapeutic for non-small cell lung cancer (NSCLC), has recently been identified as a ligand of peroxisome proliferator-activated receptor gamma (PPAR<sub>γ</sub>). However, the structural and dynamic basis of this interaction remains unclear. In this study, docking was combined with microsecond-scale molecular dynamics (MD) simulations to characterize PMX binding to the PPAR<sub>γ</sub> ligand-binding domain (LBD). PMX was observed to adopt a binding pose resembling known partial agonists, stabilized by hydrogen bonds with residues Ser289, Tyr327, and Tyr473. Energetic and conformational analyses revealed that PMX avoids deep engagement with the AF-2 surface, which is a region critical for coactivator recruitment and full transcriptional activation. Free energy landscapes, principal component analysis, and dynamic cross-correlation maps further demonstrated that PMX induces conformational dynamics consistent with a partial agonist profile. This study provides an atomistic perspective on the recognition mechanism of PMX as a PPAR<sub>γ</sub> partial agonist, offering a structural foundation for designing multitarget agents that simultaneously disrupt nucleotide metabolism and transcriptional regulation in NSCLC.
Authors
- Lei Zhang (ORCID: https://orcid.org/0000-0001-6389-8987)
- Zhiwei Yang (ORCID: https://orcid.org/0000-0001-6969-8177)
- Jiasheng Zhao
- Shengli Zhang (ORCID: https://orcid.org/0000-0002-7298-4809)
- Shunlin Ren (ORCID: https://orcid.org/0000-0003-2991-9865)
- Yunfei She
Institutions
- Hunter Holmes McGuire VA Medical Center (US)
- Virginia Commonwealth University Medical Center (US)
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Physical Chemistry Chemical Physics
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1039/d5cp03840e
- Primary Topic
- Peroxisome Proliferator-Activated Receptors
- Type
- article
- Field-Weighted Citation Impact
- 0.00